Table S4: Main Features of the M-5, M-11 and M-13 and Previous Association of These Markers with Cancer Outcome, Related with Figure 4

	CD163	CD169	CD206	CD204	CD38	CD81	PD-L1/CD274*
M-5	-	-/+	-	+	++	+	+
M-11	+	+	+	+	+	+	
M-13	-/+	-	=	+	+	+	
Reported effect	Pro-tumor macrophage associated with poor outcome	Anti-tumor immunity, CD169+ sinus macrophages in lymph node are associated with good prognosis	Pro-tumor macrophages, associsted with poor outcome	Pro-tumor macrophage associated with poor outcome	Involved in immunosuppressive function of MDSCs	Involved in immunosuppressive function of MDSCs	Involved in T cell immunosuppression and showed predictive value for immunotherapy
cancer type	Lung cancer, T cell leukemia, Hodgkin lymphoma,	Colorectal cancer, endometrial carcinoma, metastatic melanoma	Renal cell carcinoma, prostate adenocarcinoma, glioma, Hepatocellular carcinoma	Glioma, ovarian cancer, lung cancer, pancreatic cancer, esophageal cancer, upper urinary tract carcinoma and EBV associated gastric cancer		Tumor mouse model	Poor prognosis in breast cancer, clear cell renal cell carcinoma, good prognosis in high grade serous ovarian cancer
References	Yang Li et al, Oncotarget, 2015; Komohara et al, Cancer Sci, 2013; Tan K et al, Blood, 2012;	Asano et al, Immunity, 2011; Ohnishi et al, Cancer Science 2013; Saito Y et al, Cancer Immunol Res, 2015; Ohnishi K Cancer Sci, 2016	Xu L et al, Urol Oncol, 2014; Hu W et al, Oncol Lett, 2015; Ding P et al, Cell Biochem Biophys, 2014; Dong P et al, Int J Mol Sci, 2016;	Ohtaki Y et al, J Thorac Oncol,2010; Hirayama S, J Thorac Oncol, 2012; Ichimura T et al, Hum Pathol, 2016		Vences-Catalán F etal, Cancer Res, 2015	Leite KR et al, Diagn Pathol 2015; Okabe M et al, Cancer Sci, 2017; Webb JR, Gynecol Oncol, 2016; Xiangjiao M et al, Canc Treat Rev, 2015)

<sup>\*</sup>assessed only on the surface of M5